Biotechnology · Boston, Massachusetts, United States
$1.97
-1.01% (-$0.02)2026-07-09
Smart-Money SignalNeutral · 50/100— Insiders are net sellers over 90 days (-$2K, 1 sale vs 1 buy)
Net Income-$17.8M
EPS$-0.26
Market Cap$136.3M
Price Performance
Historical data including institutional events
Company Profile
J
James McArthur
CEO & Executive Director
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States.
The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1.
It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.
